R&D pipeline
The UCB pipeline delivers:
- a promising portfolio targeting severe diseases and addressing unmet medical needs
- focus on neurological and immunological diseases
- more convenient and effective treatments for patients and specialists.
UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Neurology

Immunology
Indications | Phase 1 | Phase 2 | Phase 3 | Filed | ||
---|---|---|---|---|---|---|
bimekizumab (IL17AF) | psoriasis |
![]() |
||||
psoriatic arthritis |
![]() |
|||||
axial spondyloarthritis |
![]() |
|||||
hidradenitis suppurativa |
![]() |
|||||
rozanolixizumab (FcRn) | myasthenia gravis |
![]() |
||||
immune thrombocytopenia |
![]() |
|||||
chronic inflammatory demyelinating polyneuropathy (CIDP) |
![]() |
|||||
zilucoplan (C5) | myasthenia gravis |
![]() |
||||
immune-mediated necrotizing myopathy (IMNM) |
![]() |
|||||
amyotrophic lateral sclerosis1 |
![]() |
|||||
COVID-associated acute respiratory distress syndrome (ARDS)2 |
![]() |
|||||
Staccato® alprazolam | active epileptic seizure |
![]() |
||||
dapirolizumab pegol (CD40L) | systemic lupus erythematosus3 |
![]() |
||||
UCB0107 (Tau) | progressive supranuclear palsy (PSP) |
![]() |
||||
1 Project |
![]() |
|||||
1 Project |
![]() |
1 In partnership with HEALEY ALS Platform Trial
2 In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
3 In partnership with Biogen
Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.